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Abstract
E2F7 and E2F8 act as tumor suppressors via transcriptional repres-
sion of genes involved in S-phase entry and progression. Previ-
ously, we demonstrated that these atypical E2Fs are degraded by
APC/CCdh1 during G1 phase of the cell cycle. However, the mecha-
nism driving the downregulation of atypical E2Fs during G2 phase
is unknown. Here, we show that E2F7 is targeted for degradation
by the E3 ubiquitin ligase SCFcyclin F during G2. Cyclin F binds via its
cyclin domain to a conserved C-terminal CY motif on E2F7. An E2F7
mutant unable to interact with SCFcyclin F remains stable during G2.
Furthermore, SCFcyclin F can also interact and induce degradation of
E2F8. However, this does not require the cyclin domain of
SCFcyclin F nor the CY motifs in the C-terminus of E2F8, implying a
different regulatory mechanism than for E2F7. Importantly, deple-
tion of cyclin F causes an atypical-E2F-dependent delay of the G2/
M transition, accompanied by reduced expression of E2F target
genes involved in DNA repair. Live cell imaging of DNA damage
revealed that cyclin F-dependent regulation of atypical E2Fs is
critical for efficient DNA repair and cell cycle progression.
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Introduction
The atypical E2Fs, E2F7 and E2F8, are transcriptional repressors
controlling a network of genes that drive cell cycle progression.
Our previous studies have revealed that classical E2F7/8 target
genes, such as CDT1, CDC6, and RAD51, are involved in DNA
replication, repair, and metabolism (Westendorp et al, 2012;
Kent et al, 2016). Ectopic expression of atypical E2Fs leads to
downregulation of these target genes accompanied by a permanent
S-phase arrest and severe DNA damage (Westendorp et al, 2012;
Yuan et al, 2018). In contrast, depletion of E2F7 and E2F8 leads to
upregulation of E2F targets, loss of DNA damage checkpoint
control, and spontaneous development of hepatocellular carcino-
mas (Kent et al, 2016; Thurlings et al, 2016). As such, activity of
E2F7 and E2F8 must be tightly regulated during the cell cycle and
in response to DNA damage. Nonetheless, the regulation of the
atypical E2Fs is not fully elucidated. Recently, we have shown that
APC/CCdh1 targets E2F7 and E2F8 for degradation during the G1
phase of the cell cycle and that inhibition of the APC/CCdh1-
mediated degradation of E2F7 and E2F8 impairs S-phase entry,
eventually resulting in cell death (Boekhout et al, 2016). Addition-
ally, in response to replication stress the repressor activity of atypi-
cal E2Fs is inhibited by checkpoint kinase 1 (Chk1) to prevent a
permanent cell cycle arrest (Yuan et al, 2018). These studies
demonstrated that the proper regulation of atypical E2Fs during
cell cycle progression and DNA damage is critical to avoid a detri-
mental effect on cell survival.
In previous studies, while investigating the oscillating expression
pattern of atypical E2Fs, we observed that the protein levels of E2F7
and E2F8 peak in S phase and are downregulated during the G2
phase of the cell cycle. However, the regulatory mechanism behind
the downregulation in G2 is unknown (Boekhout et al, 2016). Since
the transcript levels of E2F7 and E2F8 are only slightly lower in G2
compared to S phase, it is likely that atypical E2Fs are subjected to
proteasomal degradation during this phase of the cell cycle. Previ-
ous studies have linked the E2F family members with G2-to-M tran-
sition (Ishida et al, 2001; Polager et al, 2002; Zhu et al, 2004). In
addition to genes that are involved in DNA replication and repair, a
substantial number of mitotic genes such as CDK1, CCNB1, and
PLK1 were also identified as E2F-regulated genes. We consistently
found that E2F7 and E2F8 transcriptionally regulate a subset of
genes that are related to chromatin and cytoskeleton organization
(Westendorp et al, 2012). Together, these studies give rise to the
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research questions of how atypical E2Fs are regulated and what
their function during G2 phase is.
We thereby focused on the potential involvement of the Skp–
Cullin–F-box protein-containing complex (SCF), an E3 ubiquitin
ligase complex that controls the transition between G1/S and G2/M
phases by targeting a number of key cell cycle regulators for protea-
somal degradation (Nakayama & Nakayama, 2005). The substrate
specificity of the SCF complex is determined by the F-box protein
subunits. To date, over 70 human F-box proteins have been identi-
fied, and the founding member of the F-box family is cyclin F.
Mouse embryonic fibroblasts (MEFs) lacking cyclin F exhibited cell
cycle defects, indicating that cyclin F plays a role in cell cycle regu-
lation (Tetzlaff et al, 2004). In addition, emerging evidence supports
the importance of cyclin F in promoting the G2/M phase transition
and preventing genomic instability (D’Angiolella et al, 2010; Choud-
hury et al, 2016).
In the current study, we discovered that SCFcyclin F targets E2F7
and E2F8 for proteasomal degradation during G2 phase in human
cells. Inhibition of cyclin F-dependent E2F7/8 degradation caused a
defect in G2 progression and increased DNA damage accompanied
by downregulation of E2F target genes involved in DNA replication
and DNA repair. These findings suggest that degradation of atypical
E2Fs via cyclin F might be necessary for efficient repair of DNA
lesions during G2. Taken together, this study provides new mecha-
nistic insights into how human cells control the progression through
G2 phase of the cell cycle.
Results
E2F7 and E2F8 are subjected to Cullin-RING ligase-dependent
degradation during G2 and early M phase
Our previous study showed that E2F7 and E2F8 are substrates of
APC/CCdh1 during G1 phase and that their protein levels peak during
S phase when APC/CCdh1 is inactive (Boekhout et al, 2016).
However, protein levels of atypical E2Fs already begin to decline
during G2 phase, when APC/CCdh1 is still inactive. This suggests an
additional mechanism targeting E2F7 and E2F8 proteins for degrada-
tion in G2. To monitor the protein levels of E2F7 and E2F8 through-
out the cell cycle, HeLa cells were synchronized at the onset of S
phase by double thymidine treatment and subsequently released
into fresh medium. Both atypical E2Fs were already expressed at the
onset of the double thymidine release, and their protein levels
peaked 6 h after the release during late S phase (Figs 1A and
EV1A). Notably, the levels of E2F7 and to a lesser extent E2F8
decreased 9–12 h after release when most cells were in G2 phase.
Release from a hydroxyurea (HU) block also showed that E2F7/8
markedly decreased after 8 h when most cells were in G2
(Fig EV1B). In line with this, E2F7/8 protein levels were low in cells
treated with nocodazole, a microtubule inhibitor that arrests cells in
prophase (Fig 1B). Together these findings suggest that E2F7/8 peak
in S phase and are degraded during G2 and early mitosis.
We investigated which mechanism could be responsible for
degradation of E2F7/8 during G2 and prophase, and we reasoned
that the SCF (Skp–Cullin–F-box protein) ubiquitin ligase complex
would be a highly likely candidate (Nakayama & Nakayama, 2006).
The SCF is the largest member of E3 ligase family, and among its
many functions is the control of G2/M phase transition by proteaso-
mal degradation of key cell cycle regulators, including the
APC/CCdh1 inhibitor Emi1 (Guardavaccaro et al, 2003; Margottin-
Goguet et al, 2003; Herrero-Ruiz et al, 2014). We therefore tested
whether the Cullin-RING ligase promotes the degradation of E2F7
and E2F8 by treating HeLa cells for 16 h with MLN4924, a potent
and selective Cullin-RING ligases inhibitor (Soucy et al, 2009). To
avoid bias from effects of this inhibitor on cell cycle progression,
Hela cells were arrested in prophase with nocodazole. Under these
conditions, the degradation of the atypical E2Fs was rescued by
MLN4924, suggesting that E2F7/8 are targets of the SCF complex
(Fig 1C). To test whether Cullin-RING ligase inhibition increases the
half-life of E2F7 and E2F8, cells were treated with cycloheximide
(CHX), to inhibit protein synthesis, in the presence or absence of
MLN4924. Indeed, both E2F7 and E2F8 were stabilized by MLN4924
treatment (Fig 1D). These data demonstrate that atypical E2Fs are
subjected to degradation by the Cullin-RING ligases during G2 and
early M phase of the cell cycle.
Cyclin F binds to E2F7 and E2F8 via defined C-terminal motifs
The SCF complex selectively binds to its substrates via specific
F-box protein subunits (Nakayama & Nakayama, 2005). Since the
degradation of E2F7/8 occurred during G2 and prophase, we there-
fore hypothesize that the F-box protein cyclin F, a SCF ubiquitin
ligase complex that is also active in G2 phase, could be a putative
candidate for E2F7/8 degradation. This atypical cyclin does not
interact with cyclin-dependent kinases but instead functions as a
conserved substrate recognition subunit of the SCF ubiquitin ligase
complex. It mediates degradation of multiple proteins including
SLBP, RRM2, and CDC6 during G2 phase, to control cell cycle
progression and to maintain genome stability (D’Angiolella et al,
2012; Dankert et al, 2016; Walter et al, 2016). Previous work
demonstrated that cyclin F can bind to its substrates via a cyclin-
binding sequence (known as CY motif) which contains a hydropho-
bic patch RxL or RxI motifs (D’Angiolella et al, 2013). We mapped
three conserved putative CY motifs within murine E2F7 and four
within murine E2F8 (Fig 2A). Immunoprecipitation was performed
to examine the interaction between cyclin F and E2F7/8. We overex-
pressed EGFP-tagged E2F7 and E2F8 or only EGFP and found that
E2F7/8-EGFP, but not EGFP alone, interacts with endogenous cyclin
F (Fig EV1C). Reciprocal immunoprecipitation showed that Flag-
tagged cyclin F can also pull down exogenous E2F7/8-EGFP
(Fig EV1D).
Next, we aimed to identify the cyclin F-binding motif in E2F7/8
and mutated RxL or RxI motifs to two alanines (AxA). A series of
binding experiments using both wild-type and AxA mutants were
carried out to evaluate their interactions with cyclin F (Fig 2B). We
found that E2F7 and E2F8 with mutations at their C-terminal CY
motifs (E2F7RxL/AxA 894/896 and E2F8RxL/AxA 860/862, hereafter abbre-
viated to E2F7R894A and E2F8R860A) failed to interact with endoge-
nous cyclin F. These data provide strong evidence that cyclin F
binds to both E2F7 and E2F8 via a canonical CY motif. E2F7 and
E2F8 have highly similar amino acid sequences and these C-
terminus motifs are located at parallel positions on E2F7 and E2F8.
Furthermore, these C-terminal motifs are conserved across multiple
species (Fig EV1E) suggesting that the interaction between cyclin F
and atypical E2Fs also occurs in other species. We then performed
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co-immunoprecipitations with truncated versions of cyclin F to test
their interactions with EGFP-tagged E2F7/8. We found that a ∆270
mutant version of cyclin F, which lacks the cyclin domain, lost its
binding to E2F7 while wild-type version and other truncated
mutants still bound to E2F7 (Fig 2C). Of note, mutating the
hydrophobic patch domain (ML/AA) of cyclin F did not interfere
with its binding to E2F7. This suggests that the interaction between
cyclin F and E2F7 required the cyclin domain, but not specifically
via hydrophobic patch domain of cyclin F. EGFP-E2F8 interacted
with all truncated or mutants versions of cyclin F, indicating that
cyclin F binds via its F-box to E2F8 (Fig 2C).
E2F7 and E2F8 are targeted for ubiquitination and degradation
by cyclin F during G2/M phases
Since cyclin F interacts with atypical E2Fs, we hypothesized that
over expression of cyclin F would result in de-stabilization of wild-
type E2F7/8 but not of the E2F7R894A and E2F8R860A mutants that
show reduced interaction with cyclin F. By performing co-transfec-
tion and immunoblotting, we did indeed observe that protein levels
of wild-type E2F7 but not the E2F7R894A mutant were downregulated
by over expression of cyclin F in G2/M phases, suggesting that
cyclin F mediates degradation of E2F7 via the motif at the C-
terminus (Fig 3A). Overexpression of cyclin F decreased also the
expression of endogenous E2F7/8 (Fig EV2A). The extent of down-
regulation was similar to the effect of cyclin F overexpression on
CDC6, a known cyclin F target (Walter et al, 2016). Interestingly,
although the E2F8R860A mutant was more stabilized compared to
wild-type E2F8 in G2/M phases, both versions were downregulated
by cyclin F (Fig 3A). The E2F8R408A that showed also reduced inter-
action with cyclin F (Fig 2B) was also degraded by cyclin F
(Fig EV1F), suggesting that the degradation of E2F8 by cyclin F is
not exclusively mediated through these conserved RxL interaction
motifs.
If cyclin F targets E2F7 and E2F8 for degradation, then downreg-
ulation of cyclin F would result in stabilization of atypical E2Fs. To
test this, cyclin F was knocked down by a pool of siRNAs and the
protein expression of endogenous E2F7/8 was measured by
immunoblotting. Cyclin F knockdown resulted in increased expres-
sion of E2F7/8 compared to cells transfected with a scrambled
siRNA (Fig 3B). In line with this finding, we also showed that two
different siRNAs against cyclin F lead to stabilization of endogenous
E2F7/8 (Fig EV2B). In addition, we measured the half-life of E2F7/8




Figure 1. E2F7 and E2F8 are subjected to Cullin-RING ligase-dependent degradation during G2 and early M phase.
A Protein levels of E2F7 and E2F8 during cell cycle progression. HeLa cells were synchronized by a double thymidine block and released into fresh medium. Cells were
harvested at the indicated time points, and an asynchronous (AS) condition was used as control. Protein levels were measured by immunoblotting, and cell cycle
progression was determined by flow cytometry (shown in Fig EV1A). The asterisk indicates the E2F7-specific band.
B Decreased stability of E2F7 and E2F8 in nocodazole-arrested cells. HeLa cells were treated with either DMSO or nocodazole (50 ng/ml) for 16 h. Cells were harvested
and lysed for immunoblotting. Protein expression of cyclin B1 was used as a marker for G2 or M, and c-tubulin was used as loading control.
C Selective Cullin-RING inhibitor MLN4924 rescued the degradation of E2F7/8 under nocodazole-arrested condition. HeLa cells were treated with DMSO, nocodazole, or
nocodazole plus MLN4924 (0.1 lM) for 16 h. Cells were harvested and lysed for immunoblotting. Cyclin B1 expression was used as a marker for G2 or M cell cycle
progression, and c-tubulin was used as loading control.
D Increased half-life of E2F7/8 by MLN4924 treatment. HeLa cells were treated with cycloheximide (CHX, 50 lg/ml) either with or without MLN4924 (0.1 lM). Protein
levels of E2F7 and E2F8 were determined by immunoblotting (left panel). Asterisk indicates the E2F7-specific band. Cyclin B1 and cyclin A2 expressions were used as a
marker for G2 or M cell cycle progression, and c-tubulin was used as loading control. Quantifications (right panels) were performed based on two independent
experiments. Bar and error bars represent mean ! SEM.
Source data are available online for this figure.
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presence of cyclin F siRNA compared to the scrambled siRNA
(Fig EV2C). These data demonstrate that cyclin F targets E2F7/8 for
degradation. To determine during which phase in the cell cycle this
process occurs, we monitored the expression of atypical E2Fs
during cell cycle progression after release from a double thymidine
block in the presence and absence of cyclin F siRNA. We observed
that protein levels of cyclin F gradually increased from early S
phase and peaked 9 h after release, when most cells were in G2
phase (Figs 3C and EV2D). E2F7 levels started to decrease at that
same time point. E2F8 proteins decreased later (12 h). At 12 h,
when the majority of cells were still in G2, E2F7 and E2F8 protein
and transcript levels had almost completely disappeared (Figs 3C
and EV2D and E). Importantly, cyclin F knockdown enhanced the
protein levels of E2F7 and E2F8 at 9 h after thymidine release,
when cells were in G2 phase. The mRNA levels of E2F7 were not
affected by cyclin F knockdown (Fig EV2E), supporting that the
stabilization of E2F7 resulted from reduced proteasomal degrada-
tion. E2F8 transcript levels were slightly higher at 0 and 9 h and
lower at 3 and 6 h in cyclin F knockdown conditions compared to
scr-treated cells. This finding suggests that increased transcript
levels of E2F8 at 9 h might have contributed to the increased




Figure 2. Cyclin F binds to E2F7 and E2F8 through a defined motif at the C-terminus.
A Schematic view showing the location of putative cyclin F recognition motifs (RxL or RxI) on murine E2F7 and E2F8 proteins.
B C-terminus motifs at parallel positions on E2F7 and E2F8 are essential for binding to cyclin F. The residues on each motif were mutated to alanines (R to A, I/L to A)
with site-directed mutagenesis PCR. HEK293 cells were transfected with either EGFP-tagged empty vector (EGFP), wild-types E2F7/8 (WT), or alanine mutants.
Nocodazole (50 ng/ml) was added 32 h after transfection, and MG132 (1 lg/ml) was added 5 h before harvesting at 48 h post-transfection. Cells were harvested and
lysed for immunoprecipitation using anti-EGFP resin followed by immunoblotting with antibodies against cyclin F and EGFP.
C Schematic view showing the truncated mutants and ML/AA mutant of cyclin F (left). HEK cells were transfected with the indicated constructs, and co-
immunoprecipitation was performed using Flag resin (right).
Source data are available online for this figure.
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To verify whether cyclin F controls the stability of E2F7/8
through ubiquitin-mediated degradation, we performed in vivo ubiq-
uitination assays. Atypical E2Fs and HA-tagged wild-type ubiquitin
were co-expressed in the presence and absence of cyclin F. Then,
E2F7 and E2F8 were subjected to immunoprecipitation followed by
immunoblotting for HA-ubiquitin (Fig 3D and E). We found that
E2F7 and E2F8 were poly-ubiquitinated. Over expression of cyclin F
enhanced the ubiquitination of E2F7/8. In addition, we demon-
strated that E2F7R894A displayed a reduction in ubiquitination
compared to E2F7WT (Fig EV2F). Taken together, our data suggest





Figure 3. E2F7 and E2F8 are targeted for ubiquitination and degradation by cyclin F during G2/M.
A Wild-type or mutant versions of EGFP-tagged E2F7/8 were co-transfected with either empty vector or Flag-tagged cyclin F in HEK293 cells. Nocodazole was added
to cells 8 h before harvest. Forty-eight hours after transfection, cells were collected and lysed for immunoblotting.
B Knockdown of cyclin F stabilized E2F7 and E2F8. HeLa and RPE cells were transfected with either scramble siRNA or pool cyclin F siRNA. Cells were harvested at
48 h post-transfection. Protein levels of E2F7/8 were analyzed by immunoblotting. Asterisk indicates the specific band of E2F7 detection.
C Cyclin F targets atypical E2Fs during G2/M. HeLa cells were transfected with either scrambled siRNA (scr) or cyclin F siRNA (sicyclin F) for 24 h. Then, cells were
synchronized by double thymidine block and released into fresh medium after the second block. Cells were harvested at the indicated time points after the release.
Protein expression was measured by immunoblotting, and cell cycle progression was determined by flow cytometry (shown in Fig EV1A). Asterisk indicates the
specific detection of endogenous E2F7.
D, E Cyclin F contributes to the ubiquitination of E2F7 and E2F8 in vivo. HEK293 cells were transfected with HA-E2F7/8, with or without Flag-cyclin F, and with HA-
tagged ubiquitin. Five hours before harvest, cells were treated with MG132. Forty-eight hours after transfection, HEK cells were harvested and lysed for
immunoprecipitation pull-down assay with anti-HA resin followed by immunoblotting.
Source data are available online for this figure.
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Failure to degrade E2F7 and E2F8 results in defected
G2/M transition
Next, we aimed to investigate the biological significance of the
cyclin F-dependent degradation of atypical E2Fs. In the flow cytome-
try data from Fig EV2D, knockdown of cyclin F induced a delay in
the progression of cells through G2 or M phase, reflected by a
smaller G1 cell population at 9 and 12 h after thymidine release.
Given that protein levels of E2F7/8 were stabilized during G2 phase
upon cyclin F depletion (Fig 3C), we hypothesized that the G2/M
transition delay by cyclin F loss resulted from stabilized expression
of E2F7 and E2F8. To test our hypothesis, we analyzed whether loss
of E2F7/8 would rescue the cell cycle delay caused by loss of cyclin
F. To this end, E2F7 and E2F8 (7/8KO) were deleted in non-trans-
formed human cells—retina pigment epithelial cells (RPE-hTERT)
expressing the Fluorescent Ubiquitin Cell Cycle Indicator (FUCCI
system) using CRISPR–CAS9 technology (Sakaue-Sawano et al,
2008). RPE-hTERT cells carrying a Cas9 construct lacking a small
guiding RNA (sgRNA) were used as control (Ctrl). Complete and
permanent deletion of both E2F7 and E2F8 was confirmed by
immunoblotting (Fig EV3A). To monitor the cell cycle progression
through the G2 and M phases, these two cell lines were synchro-
nized at the onset of S phase by HU treatment for 16 h. After release
from HU, the progression of each individual cell was recorded by
live cell imaging (Fig 4A). Around 50% of Ctrl cells reached mitosis
within 24 h after HU release, while only 20% of cells with cyclin F
siRNA progressed through mitosis (Fig 4B). Importantly, the delay
in cell cycle progression induced by the knockdown of cyclin F was
completely rescued in cells with deletion of E2F7/8.
Since HU treatment results in DNA damage and loss of E2F7/8
leads to an impaired DNA damage response (Koc et al, 2004;
Zalmas et al, 2008; Aksoy et al, 2012; Thurlings et al, 2016), the
impact of cyclin F-mediated degradation of E2F7/8 was investigated
under unperturbed conditions. Similar to the setting in Fig 4A, both
Ctrl and 7/8KO cells were transfected with either scrambled siRNA or
siRNA against cyclin F and subjected to fluorescent live cell imaging.
Four cell cycle stages, i.e., G1 phase, G1–S transition, late S to G2,
and M, were analyzed based on the fluorescence signal (see Materi-
als and Methods). For each condition, 50 cells were followed and
their cell cycle progression starting from G1 phase was recorded
(Fig 4C). We found that 70% of the Ctrl cells (35/50) completed
mitosis during the observed time window, while cyclin F knock-
down resulted in a delayed cell cycle progression with only 44%
(22/50) of all cells finishing mitosis in the same time period
(Fig 4D). In line with the HU-synchronized cells, deletion of E2F7/8
could rescue the delayed cell cycle progression induced by cyclin F
knockdown under unperturbed conditions, with 60% of scrambled
siRNA 7/8KO cells completing mitosis within 24 h compared to 58%
(29/50) of cyclin F siRNA 7/8KO cells. Moreover, the time from G1–S
transition to mitosis for those cells that completed this process was
measured (Fig 4E). We found that Ctrl cells with cyclin F siRNA
moved from S-phase entry to completion of mitosis in an average
time of approximately 18 h, compared to < 16 h in Ctrl cells incu-
bated with scrambled siRNA. This delayed cell cycle progression
phenotype was absent in the 7/8KO cell lines treated with cyclin F
siRNA; they also needed < 16 h to complete mitosis from the
moment of S-phase entry. We also quantified the fates of the whole
cell population (50/each, at the last frame of the live imaging).
Strikingly, 42% of the Ctrl cells with cyclin F knockdown were in
late S or G2, compared to only 18% in scrambled condition (Fig 4F;
individual cells are shown in Fig EV3B). More importantly, such
delay was not observed in the 7/8KO cells, suggesting that the delay
in S and/or G2 progression by cyclin F knockdown is a consequence
of stabilized E2F7/8.
Overexpression of E2F7R894A mutant delays G2–M progression
If cyclin F-dependent degradation of atypical E2Fs is important for
G2/M progression, then a non-degradable version of an atypical E2F
should slow down cell cycle progression. To test this, we first
compared the appearance of E2F7WT and E2F7R894A proteins when
adding doxycycline immediately after HU release (Fig 5A).
Immunoblotting analysis revealed that 6–12 h after the addition of
doxycycline, the protein levels of mutant version E2F7R894A were
increased compared to E2F7WT, whereas mRNA levels of E2F7R894A
were lower than those of E2F7WT (Fig 5B). This finding excluded
the possibility that the enhanced expression of E2F7R894A was
related to higher transcript levels. Then, we compared the G2/M
progression between the HeLa cell lines in which either E2F7WT or
E2F7R894A was induced by doxycycline after HU release (Fig 5C). In
this live cell imaging assay, over expression of E2F7WT caused a
minor cell cycle delay toward mitosis (log-rank P = 0.054), while
E2F7R894A significantly reduced the number of cells finishing mitosis
after 24 h (log-rank P < 0.01). Interestingly, we found the c-H2AX
level was significantly higher in cells expressing E2F7R894A than
E2F7WT, suggesting that expressing E2F7R894A induced DNA damage
and thereby delayed cell cycle progression (Fig EV3C). Together,
these data demonstrated that expression of mutant version
E2F7R894A resulted in delayed G2–M progression.
Cyclin F controls transcription of DNA repair genes via
degradation of E2F7/8
To determine in an unbiased manner which transcripts are regulated
by atypical E2Fs in a cyclin F-dependent manner, we performed
RNA sequencing on nocodazole-synchronized cells treated with
scrambled (scr), cyclin F, E2F7/8, or cyclin F/E2F7/8 (triple) siRNAs.
We observed a substantial overlap between genes that were down-
regulated by cyclin F siRNA compared to scr, and genes that were
upregulated in cyclin F/E2F7/8 siRNAs compared to cyclin F siRNAs
(Figs 6A and EV4A). Gene ontology analysis showed that these
genes, which were downregulated genes after cyclin F knockdown
and rescued by additional E2F7/8 knockdown, were strongly
enriched for DNA repair and replication pathways (Figs 6B and
EV4B, Dataset EV1). Among these DNA repair genes, we observed
many known E2F7/8 target genes, such as RAD51, MSH2/6, EXO1,
and CHEK1 (Westendorp et al, 2012). Quantitative PCR and
immunoblotting on a subset of these DNA repair genes confirmed
that they were indeed downregulated by cyclin F depletion in an
E2F7/8-dependent manner (Fig 6C and D). Consistently, the expres-
sions of E2F7/8 target genes involved in DNA replication showed a
similar expression pattern (Fig 6C, lower panel). We also confirmed
this finding in RPE cells (Fig EV4C). Interestingly, we found that
genes known to control mitotic entry, such as PLK1 (polo-like
kinase 1) and CCNB1 (cyclin B1), were upregulated in response to
cyclin F knockdown (Fig EV4D), but were not affected by
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Figure 4. Failure to degrade E2F7 and E2F8 results in delayed G2/M progression.
A Schematic view of the experimental setting for the HU-synchronized live cell imaging. Forty-eight hours before imaging, RPE-FUCCI cells were transfected with siRNA
against scramble or cyclin F. Sixteen hours before imaging, cells were synchronized at the G1/S border by HU (2 mM) treatment. Representative images from different
channels are shown, and white arrows in differential interference contrast (DIC) channel indicate the traced cell. Scale bar: 10 lm.
B Quantification of the number of Ctrl (left panel) and 7/8KO (right panel) RPE-FUCCI cells with scr or sicyclin F that completed mitosis after HU release. For each
condition, 100 cells were monitored by live cell imaging. Each cell was followed until it successfully finished mitosis and divided into two daughter cells for a
maximum of 24 h. Log-rank tests were performed to analyze the statistical significance.
C Schematic view of the experimental setting for live imaging of asynchronous cells. Forty-eight hours before imaging, RPE-FUCCI cells were transfected with siRNA
against scramble or cyclin F. At the start of the imaging, G1 cells (red: mKO2-Cdt1 > mAG1-Geminin, 50 cells per condition) were enrolled and subsequently
monitored though their entire cell cycle until mitosis. The black dot represents mitosis.
D Knockdown of cyclin F causes a delay in mitotic entry that is dependent on E2F7 and E2F8. The number of Ctrl (left panel) or 7/8KO (right panel) RPE-FUCCI cells with
scr or cyclin F RNAi that finished mitosis during live cell imaging is shown. For each condition, 50 cells at G1 were monitored by live cell imaging. Each cell was
followed until it successfully progressed through S and G2 phases, finished mitosis, and divided into two daughter cells, for a maximum of 24 h. Log-rank tests were
performed to analyze the statistical significance.
E Loss of cyclin F delays the progression from G1/S transition to mitosis. Histogram shows the time from G1/S (mAG1-Geminin intensity increases to higher than 10%
of the maximum value in three consecutive imaging frames) to completed mitosis. Only cells that finished mitosis were enrolled in this quantification. Student’s
t-test was used to test the statistical significance, and asterisks indicate the P < 0.01. Bar and error bars represent mean ! SEM.
F Depletion of cyclin F stalls the cell cycle at late S/G2. After 24 h of live cell imaging, the cell cycle progression from panel (E) was quantified. Histogram shows the
percentage of cells at each stage (at 24 h) over the whole population (50 cells per condition).
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knockdown of atypical E2Fs. This is in line with a previous study
where it has been shown that cyclin F suppresses a B-Myb-driven
transcriptional program regulating mitotic gene expression (Klein
et al, 2015). Phosphorylated MPM2 as an indicator of M phase was
slightly increased in sicyclin F and siTriple conditions compared to
scr and siE2F7+8 conditions, suggesting that depletion of cyclin F
also affects mitotic entry through regulation of B-Myb target gene
expression (Fig EV4E).
Degradation of atypical E2Fs sustains DNA repair functions in G2
Multiple DNA damage repair pathways, including mismatch repair
(MMR), nucleotide excision repair (NER), base excision repair
(BER), and homologous recombination (HR), are regulated by atypi-
cal E2Fs in a cyclin F-dependent manner (Fig 6B). We wondered if
these transcriptional effects of cyclin F depletion would have func-
tional consequences. Therefore, we tested if HR repair was impaired
in cyclin F-depleted cells (Parvin et al, 2011). We found that knock-
down of cyclin F significantly reduced HR repair efficiency, and this
repair deficiency was fully recovered by additional knockdown E2F7
and E2F8 (Figs 7A and EV5A; see Materials and Methods).
If failure to degrade atypical E2Fs resulted in enhanced
repression of DNA damage repair genes, then DNA lesions would
accumulate. To test this idea, the level of phosphorylated c-H2AX
was measured using immunofluorescence staining in nocodazole-
arrested cells (Fig 7B). Indeed, loss of cyclin F resulted in a
significant increase of c-H2AX levels, when compared with the
scrambled condition. In addition, combined knockdown of E2F7/8
and cyclin F rescued the DNA lesions, suggesting that DNA repair
capacity during G2 was restored by sustaining E2F-dependent DNA
repair gene expression.
To monitor the dynamics of DNA damage repair by live cell
imaging, a truncated version of 53BP1-mApple construct was inte-
grated into RPE cells (Yang et al, 2015). In response to DNA
damage, mApple-tagged 53BP1 localizes to damage sites, which can
be seen as bright foci. Therefore, measurement of the numbers of
53BP1 foci in the nucleus can be used to monitor the onset and
repair of DNA damage. RPE cells stably expressing this construct
were transfected with siRNA targeting cyclin F or E2F7/8 and then
treated with HU for 16 h to arrest the cell cycle at the onset of S
phase before live cell imaging. We first quantified the number of
53BP1 foci in the nucleus at the start of HU release. Interestingly, in
the non-treated conditions, knockdown of cyclin F significantly
increased the number of 53BP1 foci compared to scrambled siRNA
(Fig EV5B). Furthermore, combined knockdown of cyclin F and
E2F7/8 attenuated this increase, suggesting that DNA damage repair
function was restored. This result indicated again that the cell cycle
delay caused by loss of cyclin F was due to a decrease in DNA repair
capacity by enhanced repressor activity of E2F7/8. We noticed that
the average number of 53BP1 foci per nucleus was significantly
higher in scr and sicyclin F conditions compared to siE2F7+8 and
siTriple conditions when cells were synchronized with HU
(Fig EV5B). This result suggested that depletion of E2F7 and E2F8




Figure 5. Overexpression of E2F7R894A mutant delays G2/M progression.
A Disruption of cyclin F binding site increased stability of E2F7. E2F7WT and E2F7R894A constructs were integrated in to HeLa/TO system. Cells were arrested with HU for
16 h before releasing into doxycycline containing medium, and cells were collected every 3 h for immunoblotting.
B qPCR showing that mRNA level of E2F7WT and E2F7R894A was at comparable levels. Bar and error bars represent mean ! SEM.
C Over expression of E2F7R894A delays cell cycle progression through G2–M phase. HeLa/TO cells expressing either wild-type or mutant version of E2F7 were arrested
with HU for 16 h, and then, cells were released into fresh medium with or without doxycycline. Live cell imaging was performed to trace the G2–M progression of
HeLa/TO cells.
Source data are available online for this figure.
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the loss of cyclin F but also to an even higher level. This is consis-
tent with our RNA-seq data showing that siE2F7+8 and siTriple had
enhanced expression of DNA repair genes compared to the control
and sicyclin F conditions. We then quantified the DNA damage
recovery time (from HU release until all 53BP1 foci disappeared)
and cell division events of individual cells (Fig 7C and D). We found
that loss of cyclin F significantly lengthened the damage recovery
time to 16.4 h, compared to 11.1 h of scrambled condition. Further-
more, a substantial number of sicyclin F cells failed to recover from
DNA damage within 24 h, compared to scrambled control (Fig 7C).
Most importantly, the DNA damage recovery time decreased to a
length similar to the scrambled group by additional knockdown of
E2F7/8, indicating that the delay of damage recovery was dependent
on the atypical E2Fs functions. To further investigate when the DNA
damage repair occurs after HU release, we measured the average
53BP1 foci number over time (Fig EV5C). We found that depletion
of cyclin F caused a prolonged recovery from 53BP1 at 6–8 h after




Figure 6. Cyclin F regulation of DNA replication and DNA repair genes is dependent on E2F7/8.
A Heatmap showing differentially expressed genes after cyclin F knockdown, and rescued by additional E2F7/8 depletion. Highlighted genes are all involved in DNA
repair. HeLa cells were arrested with nocodazole for 16 h prior to harvesting to minimize bias from potential differences in cell cycle progression between the
different conditions.
B KEGG pathway analysis of genes downregulated by cyclin F knockdown, and rescued by additional E2F7/8 depletion. Bars represent "log P-values, such that larger
values mean stronger statistical significance. The cutoff P-value 0.05 is shown as a red dotted line.
C qPCR showing the RNA expression of atypical E2F target genes that are involved in DNA replication or DNA repair. HeLa cells were transfected for 48 h with siRNAs
as indicated. Cells were incubated with nocodazole for 16 h before harvesting. Data represent averages ! SEM (n = 3); *P < 0.05 or **P < 0.01 (Student’s t-test). n.s.:
not significant.
D Immunoblotting showing the protein levels of Chk1 and RAD51 in the indicated siRNA conditions. HeLa cells were treated with nocodazole for 16 h prior to
harvesting.
Source data are available online for this figure.
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cells progressed to G2 phase (Fig EV5D), supporting our reasoning
that cyclin F-dependent degradation of E2F7/8 impacts on G2
progression through regulation of DNA damage repair.
Discussion
In the current study, we demonstrated a biological model that cyclin
F-dependent degradation of atypical E2Fs is critical for DNA repair
and G2-phase progression (Fig 8). We first showed that E2F7 and
E2F8 are targeted for degradation by cyclin F during G2/M phases.
In an unperturbed cell cycle, cyclin F promotes the degradation of
atypical E2Fs to allow a timely G2/M transition. Previous studies
demonstrated that cyclin F functions as a key regulator of the cell
cycle (Tetzlaff et al, 2004; Choudhury et al, 2016, 2017). CCNF, the
gene encoding cyclin F, is highly conserved across different species.
Moreover, its function is essential in the embryonic development of
mice (Tetzlaff et al, 2004). MEFs (mouse embryonic fibroblasts)
A B
C D
Figure 7. Degradation of atypical E2Fs maintains DNA damage repair.
A Loss of cyclin F induced E2F7/8-dependent homologous recombination deficiency. HeLa cells that were stably transformed with pDR-GFP were transfected with siRNA
as indicated. Forty-eight hours after the initial transfection, cells were harvested for flow cytometry. GFP-positive cells were gated (Fig EV5A). Relative HR efficiency
was adjusted to the scramble siRNA condition. Data represent averages ! SEM (n = 3); **P < 0.01 (Student’s t-test). n.s.: not significant.
B Loss of cyclin F induced E2F7/8-dependent c-H2AX accumulation. HeLa cells were transfected with the indicated siRNA for 24 h and then treated with nocodazole for
16 h before fixation for immunofluorescence staining of c-H2AX. DAPI was used to stain the cell nucleus. Relative intensity of c-H2AX was quantified by ImageJ
software, and 150 cells were quantified for each condition. Red bars represent averages; **P < 0.01 (Student’s t-test). n.s.: not significant. Scale bar 20 lm.
C Loss of cyclin F increased DNA damage recovery time before cell division. RPE cells integrated with the 53BP1 construct were transfected with the indicated siRNA for
24 h and then treated with HU for 16 h. At the beginning of the imaging, only the single cells with at least one 53BP1 focus were traced, till the time frame that no
53BP1 foci were observed. The mitotic progression of the cells was defined as the duration from damage recovery to cell division. Histogram shows the damage
recovery time (green) and the mitotic progression (black) of 50 cells for each condition. Chi-square analysis was performed to test the statistical significance
(P < 0.01).
D Knockdown of cyclin F caused a delay in DNA lesion recovery that is dependent on E2F7/8. The cumulative curves represent the add-up number of cells that overcome
the DNA damage lesions, for a time frame of 24 h. For each condition, 50 cells were quantified. Log-rank tests were performed to analyze the statistical significance.
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derived from Ccnf"/" mice show reduced population doubling times
and a delay in cell cycle re-entry from quiescence, indicating that
cyclin F is required for cell proliferation. Interestingly, this slow-
down in cell cycle re-entry may be partially explained by the inhibi-
tion of APC/CCdh1 by cyclin F during G0/G1 phase. Cdh1 is a
substrate of cyclin F, and deletion of cyclin F resulted in stabiliza-
tion of Cdh1 and inhibition of S-phase entry (Choudhury et al,
2016). However, it is important to note that cyclin F expression is
low at G0/G1 and gradually increases after S phase, and most of
cyclin F-mediated degradation occurs during G2 phase (D’Angiolella
et al, 2012) (also shown in Fig 3C). These findings raised the ques-
tion whether cyclin F regulates G2-phase progression and, if it does,
by which mechanism. In this study, we showed that cyclin F knock-
down leads to an E2F7/8-dependent G2/M transition delay. Most
importantly, by using single live cell imaging, we demonstrated that
this G2/M transition delay was likely due to a prolonged DNA repair
period (Fig 7C). Cyclin F induces the degradation of E2F7/8 to
maintain the expression of DNA repair genes, thereby ensuring
flawless cell cycle progression through G2 until mitotic entry. Previ-
ous studies have shown that cyclin F can also regulate mitotic entry
by suppressing B-Myb activity which promotes accumulation of
crucial mitosis-promoting proteins (Klein et al, 2015). Our results
are in line with this, because we observed that expression of key
regulators of mitotic activity, such as PLK1 and CCNB1, was
upregulated in cyclin F-depleted cells (Fig EV4D). These findings
highlight two distinct roles of cyclin F during G2: regulation of DNA
damage repair activity and preventing premature mitosis entry,
through degradation of E2F7/8 and suppressing B-Myb, respec-
tively.
Another central function of cyclin F is its role in guarding cells
against genotoxic stress and genomic instability during the cell
cycle. It has been shown that cyclin F promotes the degradation of
the centrosomal protein CP110 and the DNA replication protein
CDC6, thereby ensuring mitotic fidelity and preventing DNA re-
replication (D’Angiolella et al, 2010; Walter et al, 2016). Moreover,
cyclin F targets the ribonucleotide reductase RRM2 and stem loop
binding protein SLBP for proteasomal degradation, which provides
a balanced dNTP pool for DNA repair, and prevents SLBP-depen-
dent accumulation of H2AFX mRNA translation to reduce suscepti-
bility to genotoxic stress (D’Angiolella et al, 2012; Dankert et al,
2016). In line with these findings, our data demonstrate that cyclin
F sustains the expression of DNA repair genes such as RAD51,
CHEK1, and BRCA1, through degradation of the atypical E2Fs in G2
phase. Interestingly, in response to irradiation, cyclin F has been
shown to be downregulated in an ATR-dependent manner, which
resulted in stabilization of SLBP and RRM2 to promote DNA repair
(D’Angiolella et al, 2012; Dankert et al, 2016). Interestingly, both
SLBP and RRM2 are bona fide targets of E2F7/8 (Westendorp et al,
2012; Kent et al, 2016). Therefore, we hypothesized that cyclin F
controls SLBP and RRM2 expression at two different levels: directly
via their ubiquitin-dependent degradation and indirectly via degra-
dation of the transcriptional repressors E2F7/8. These complex regu-
lation mechanisms mediated by cyclin F could be significant to the
cancer field, since aberrant expression of RRM2 has been found in
multiple types of cancers and failure to maintain the balance of
dNTP can cause genome instability (Xu et al, 2008; Kumar et al,
2011; Ahluwalia & Schaaper, 2013).
In addition to RRM2 and SLBP, cyclin F targets CDC6 for degrada-
tion, which is also transcriptionally regulated by atypical E2Fs
(Westendorp et al, 2012; Kent et al, 2016). Thus, E2F-dependent
transcription and SCFcyclin F appear to have partially overlapping
functions. Therefore, the repressor functions of atypical E2Fs could
potentially compensate for the loss of cyclin F. In addition, failure to
degrade these overlapping targets (such as CDC6) in G2 phase could
result in the re-initiation of DNA replication leading to genome
instability (Walter et al, 2016). Therefore, we hypothesized that
atypical E2Fs might act as a fail-safe mechanism to repress
the expression of key cell cycle genes in case of inactivation of
SCFcyclin F. Such a compensation mechanism could help to minimize
the occurrence of genome instability.
A recent study demonstrated that activator E2Fs (E2F1-3A) are
also targeted by cyclin F for degradation during S and G2 phases
(Clijsters et al, 2019). It raises a question whether the degradation
of activator E2Fs and atypical E2Fs by cyclin F occurs simultane-
ously. Interestingly, a recent in vivo study demonstrated that there
is a distinct difference in the timing of downregulating activator and
atypical E2Fs (Cuitino et al, 2019). It was shown that E2F3A protein
levels decrease in the middle of S phase, while E2F8 downregulation
begins in late S phase. In addition, failure to degrade activators E2Fs
or atypical E2Fs had distinct consequences on the cell cycle progres-
sion: E2F activator mutants that are unable to bind cyclin F induced
premature S-phase entry, whereas non-degradable E2F7 mutants
Figure 8. Biological model of the current study.
Schematic model of the current study. In an unperturbed G2 phase, cyclin F
promotes the degradation of the transcription repressors E2F7/8, which leads to
enhanced expression of their target genes, such as RAD51, CHEK1, and MSH2
(left). Therefore, cyclin F-dependent degradation of E2F7/8 sustains the
expression of DNA repair genes before mitosis. Inactivation of cyclin F results in
stabilization of E2F7 and E2F8 in G2 phase (right). Active E2F7/8 at this stage
repress the expression of DNA repair genes, leading to accumulation of DNA
damage and delayed cell cycle progression.
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delayed G2–M progression. These findings suggested that a proper
cell cycle progression relies on a distinct regulation of activator E2Fs
and repressor E2Fs by cyclin F. It is currently unclear how cyclin F
can induce degradation of activator and atypical E2Fs at different
time points of cell cycle, but it might depend on additional post-
translational modification on E2Fs. Our data indicate that the biolog-
ical significance to keep an intermediate level of E2F7/8 during the
G2 phase is most likely to support DNA damage repair before a cell
can enter mitosis. This is in line with our previous work, which
showed that the DNA replication stress kinase Chk1 phosphorylates
E2F7/8 to inhibit its transcriptional repressor function on DNA
repair genes and thereby promotes DNA lesion recovery upon repli-
cation stress (Yuan et al, 2018). Moreover, two recent studies indi-
cated that loss of E2F7 conferred resistance to DNA damaging drugs
by elevating expression of DNA repair genes such as RAD51, BRIP1,
and FANCE (Clements et al, 2018; Mitxelena et al, 2018). These
results raise the question whether stabilization of E2F7/8 would in
turn sensitize cancer cells toward chemotherapy.
To conclude, our study discovered a novel regulatory mechanism
for atypical E2Fs whereby cyclin F mediates degradation during the
G2 phase of the cell cycle. Degradation of E2F7 and E2F8 is of
importance for proper G2 progression as depletion of cyclin F leads
to a defect in cell cycle progression that depends on atypical E2Fs.
Moreover, we provide novel insights into the regulation of DNA
damage repair gene expression during G2/M phases, in which cyclin
F-mediated degradation of atypical E2Fs promotes DNA damage
repair by sustaining DNA repair gene transcription.
Materials and Methods
Cell culture, cell line generation, and transfection
HeLa, hTERT-RPE1, and HEK 293T cell lines were purchased from
ATCC and cultured in DMEM (41966052; Thermo Fisher Scientific)
containing 10% fetal bovine serum (10500064; Life Technologies).
The HeLa cell line stably transformed with pDR-GFP was a gift from
Prof. Dr. M.A.T.M. (Marcel) van Vugt, University of Groningen, The
Netherlands. Site-directed mutagenesis was performed by a two-step
PCR amplification (PCR protocol and primers are provided in
Table EV1). Successful mutations were confirmed by Sanger sequenc-
ing (Macrogen, Inc.). Other drugs used in this study are as follows:
Nocodazole (50 ng/ml, M1404; Sigma-Aldrich); Hydroxyurea (2 mM,
H8627; Sigma-Aldrich); Thymidine (2 mM, T9250; Sigma-Aldrich);
Cycloheximide (50 lg/ml, 01810; Sigma-Aldrich); MLN4924
(0.1 lM, MLN-4924; Active Biochem); and MG132 (1 lg/ml, Peptide
International, IZL-3175-v_5mg).
To transfect HEK cells, 130 lg/ml PEI (Polyethylenimine, 23966;
Polysciences) was mixed with the desired plasmids (15 lg) contain-
ing DMEM (ratio of 1:1). Mixtures were added directly to the cells
and incubated for 6 h before being replaced with fresh media. ON-
TARGETplus Smartpool siRNAs (2 nM) were products from GE
Dharmacon; siRNA transfection was carried out according to the
manufacturer’s protocol using RNAiMAX (13778075; Thermo Fisher
Scientific). The following siRNAs were used: Dharmacon L-003215-
00-0005 (sicyclin F), Thermo Fisher HSS175354 Thermo Fisher
HSS128758/HSS128760 (siE2F8), and Dharmacon D-001210-02-05
(Scrambled).
The lentiviral construct containing a truncated version of 53BP1
tagged with mApple was obtained from Addgene (Apple-53BP1trunc
was a gift from Ralph Weissleder (Addgene plasmid # 69531; http://
n2t.net/addgene:69531; RRID:Addgene_69531)). Lentivirus was
produced by transfecting HEK 293T cells with 10ug lentiviral pack-
aging plasmids (1:1:1) and 10 lg of the 53BP1 construct with PEI
for 2 h. Then, 10 ml fresh medium was added and virus was
harvested after 48 h. Three milliliters of virus containing medium
and polybrene (8 lg/ml) was added to RPE cells for an incubation
of 24 h. RPE cells containing the construct were selected with puro-
mycin (1.0 lg/ml) for 5 days.
Immunoprecipitation and immunoblotting
Cells were washed twice with cold PBS and collected by scraping
and spinning. Cells were lysed in RIPA buffer composed of
50 mM Tris–HCl, 1 mM EDTA, 150 mM NaCl, 0.25% deoxycholic
acid, 1% Nonidet P-40, 1 mM NaF and NaV3O4, and protease
inhibitor cocktail (11873580001; Sigma-Aldrich) for 30 min on ice.
Then, lysates were centrifuged at 12,000 g for 10 min to collect
supernatants. Finally, Laemmli buffer was added, and the samples
were subjected to SDS–PAGE and immunoblotting. For immuno-
precipitations, cells were lysed in RIPA buffer and immunoprecip-
itations were carried out by incubating 20 ll of anti-FLAG M2
Affinity Gel (A2220; Sigma-Aldrich) or GFP-Trap (gta-20; Chro-
motek). After the pull-down, the agarose beads were washed
three times with RIPA and PBS before proceeding to a standard
SDS–PAGE and immunoblotting. All antibodies used in this paper
are listed in Table EV1.
Flow cytometry
Cells were harvested by trypsinization and subsequent fixation with
70% ethanol and overnight storage at 4°C. Before staining, cells
were washed twice with ice-cold Tris-buffered saline (TBS) and re-
suspended with 500 ll staining buffer that contained 20 lg/ml
propidium iodide (P4170; Sigma-Aldrich), 250 lg/ml RNase A
(RNASEA-RO; ROCHE), and 0.1% bovine serum albumin (A8531;
Sigma-Aldrich). Samples were loaded on a BD FACSCanto II flow
cytometer. Cell cycle analysis was conducted using the Cell Cycle
analysis function from FlowJo v10.0 software.
RNA sequencing
Total mRNA was collected using Qiagen’s RNeasy kits. Sequencing
libraries were then prepared using the TruSeq Poly-A kit, according
to the manufacturer’s instructions. All 16 samples were pooled into
one lane of an Illumina NextSeq 500 sequencer. Quality of the raw
sequencing data was first checked using the program FastQC. Then,
sequencing reads were trimmed for adapter sequences and mapped
to the human genome (assembly hg38) using STAR version 2.4.2a.
All mapped reads were counted using HTSeq version 0.6.1 in union
mode. Library preparation, sequencing, and mapping were
performed at the Utrecht Sequencing Facility (USEQ). The raw count
data were then used to perform differential expression analysis
using DESeq2. Heatmaps were created using the software package
pheatmap, and represent fold changes calculated from normalized
count data.
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Live imaging
For live cell imaging, 4,000 RPE-FUCCI cells were seeded into a
glass-bottom l-Slide 8-well plate. siRNA transfections were carried
out the next day, and imaging started at 48 h after cell seeding. A
Nikon Stochastic Optical Reconstruction Microscope (A1R-STORM)
was used for live imaging. For each condition, 5 × 5 fields (63×
magnification/field) were obtained. Auto-focus was set to capture
photographs from GFP (488 nm), RFP/mApple (555 nm), and dif-
ferential interference contrast (DIC) channels every 20 min for 24 h.
The software NIS-Elements version 4.51.01 was utilized for the
quantification. For the HU arrest/release experiment, 100 cells were
traced manually under the DIC channel as previously described
(Yuan et al, 2018). For the asynchronized experiment, the quality of
the movies was first improved with the auto-scale rolling balls option,
with the radius set to 30. Each cell was marked and traced with the
ROI (region of interest) function. In total, 50 individual cells were
selected for each condition, and one additional blank ROI was made
to rule out the background signal. The fluorescence intensity from
480- and 560-nm channels (based on each selected ROI) was obtained
with the “Time measurement” option in ROI panel. Cell cycle stages
were determined by the fluorescence signal intensities of CDT1-
mKusabira Orange (mKO) and Geminin-mAzami Green (mAG): G1
stage: red, mKO signal > mAG signal; G1–S transition: yellow, mAG
signal increases to 10% of maximum in three consequent frames; late
S to G2: green, mAG signal > mKO signal; and M to early G1: color-
less, disappearance of mAG signal, and evidence of mitotic division
from differential interference contrast (DIC) image.
For quantification of 53BP1 foci in Fig EV5B, cell image was
obtained from each time point and 50 cells per condition were
randomly selected for foci counting.
Quantitative PCR
Isolation of RNA, cDNA synthesis, and quantitative PCR were
performed based on the manufacturers’ instructions for QIAGEN
(RNeasy Kits), Thermo Fisher Scientific (cDNA synthesis Kits), and
Bio-Rad (SYBR Green Master Mix), respectively. Gene transcript
levels were determined using the DDCt method for multiple-refer-
ence gene correction. b-Actin and GAPDH were used as references.
qPCR primer sequences are provided in Table EV1.
CRISPR–CAS9 knockout
RPE-hTERT-FUCCI cells (a kind gift from Prof. Rene Medema,
Netherlands Cancer Institute) were transduced with a lentiviral
expression vector encoding both Flag-tagged Cas9 and a single guide
(sg) RNA sequence against E2F7 (sgRNA #1: GTGCTGCCAGCCCA
GATATA, sgRNA #2: GAGCTAGAAACTTCTGGCAC) or E2F8
(sgRNA #1: GTTCCTCTGCCACTTCGTCA, sgRNA #2: GATCTCTGTT
GCGGATCTCA) cloned into a pSicoR backbone as previously
described (van Diemen et al, 2016). Lentiviral particles were
produced by co-transfecting the pSicoR construct with third-genera-
tion packaging plasmids into 239T cells. The sgE2F7 and sgE2F8
vectors contained puromycin and blasticidin resistance cassettes,
respectively, thus allowing for sequential selection of E2F7 and E2F8
mutant clones by manual picking. Indel mutations were confirmed
with Sanger sequencing, and complete deletion of E2F7 and E2F8 was
verified by immunoblotting for E2F7/8. Cells expressing the vector
containing only Cas9, but no sgRNA, served as control cell lines.
Statistical analysis
Immunoblot, immunoprecipitation, flow cytometry, FACS sorting,
and qPCR results were repeated three times unless otherwise
described in the figure legends. Statistical analyses on qPCR were
analyzed by Student’s t-test. Statistical test on Fig 5C was analyzed
by chi-square test, and cumulative curves from Figs 4B and C, and
5D were analyzed by log-rank tests.
Data availability
The RNA-sequencing data have been deposited in NCBI’s Gene
Expression Omnibus (Polager et al, 2002) and are accessible
through GEO Series accession number GSE133416 (https://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE133416). Downregu-
lated genes in cyclin F knockdown and rescued by additional E2F7/8
knockdown are shown in Dataset EV1.
Expanded View for this article is available online.
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